[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=270f9645c897c394b5ea59e9ebe1ae0eeb88e1d102a1afa9b16b99ec29b40d6c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746635880,
      "headline": "Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
      "id": 134343224,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=270f9645c897c394b5ea59e9ebe1ae0eeb88e1d102a1afa9b16b99ec29b40d6c"
    }
  },
  {
    "ts": null,
    "headline": "Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course",
    "summary": "Crispr Therapeutics AG shows promise with innovative gene therapies like CTX-310, strong cash reserves, and a bullish long-term outlook. Click for my CRSP update.",
    "url": "https://finnhub.io/api/news?id=7f0c5991a1697f6d8c9da836905421ea7ad0f6d9563d169bce3abd345d091ffb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746633801,
      "headline": "Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course",
      "id": 134305132,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1440537288/image_1440537288.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Crispr Therapeutics AG shows promise with innovative gene therapies like CTX-310, strong cash reserves, and a bullish long-term outlook. Click for my CRSP update.",
      "url": "https://finnhub.io/api/news?id=7f0c5991a1697f6d8c9da836905421ea7ad0f6d9563d169bce3abd345d091ffb"
    }
  },
  {
    "ts": null,
    "headline": "VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations",
    "summary": "Sales from VRTX's new drugs, Casgevy, Alyftrek and Journavx, in Q1 fell short of investor expectations.",
    "url": "https://finnhub.io/api/news?id=4ec6efbe6ac5db6c09299e4aa8ba1683848efd94d9d8ae9e0e1750fcf6ab7f9d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746617160,
      "headline": "VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations",
      "id": 134316969,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Sales from VRTX's new drugs, Casgevy, Alyftrek and Journavx, in Q1 fell short of investor expectations.",
      "url": "https://finnhub.io/api/news?id=4ec6efbe6ac5db6c09299e4aa8ba1683848efd94d9d8ae9e0e1750fcf6ab7f9d"
    }
  },
  {
    "ts": null,
    "headline": "Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip",
    "summary": "Vertex missed Wall Street's Q1 estimates and announced a pause with an early-stage study of its mRNA cystic fibrosis drug.  This biotech stock should still generate exceptional returns over the next few years.  Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week.",
    "url": "https://finnhub.io/api/news?id=b7f21d959989365dbad47f561319f9949ca79f1bbcb1afda64332ea11d2b2a86",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746607740,
      "headline": "Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip",
      "id": 134316970,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex missed Wall Street's Q1 estimates and announced a pause with an early-stage study of its mRNA cystic fibrosis drug.  This biotech stock should still generate exceptional returns over the next few years.  Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week.",
      "url": "https://finnhub.io/api/news?id=b7f21d959989365dbad47f561319f9949ca79f1bbcb1afda64332ea11d2b2a86"
    }
  },
  {
    "ts": null,
    "headline": "1 S&P 500 Stock with Impressive Fundamentals and 2 to Ignore",
    "summary": "The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.",
    "url": "https://finnhub.io/api/news?id=600d1df32355c823b8eefee4731a29281618396c9e2b8fa21b878767dab7c4be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746592309,
      "headline": "1 S&P 500 Stock with Impressive Fundamentals and 2 to Ignore",
      "id": 134290416,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.",
      "url": "https://finnhub.io/api/news?id=600d1df32355c823b8eefee4731a29281618396c9e2b8fa21b878767dab7c4be"
    }
  }
]